title: [The prognostic indicators of development of ATRA-syndrome under treatment of acute promyelocyte leucosis].
abstract: The application of all-trans-retinoic acid (ATRA) in the protocols of treatment of acute promyelocyte leucosis provided the achievement of 95% of full remissions and fast correction of coagulopathy. Besides, ATRA along with positive impact can exert the side effects, among which the most dangerous is the differentiation syndrome. On the basis of analysis of clinical signs, biochemical, hemostasiologic and morphologic blood indicators it is established that among prognostic criteria of differentiation syndrome development are presence of febrile temperature, decrease of content of thrombocytes lesser than 20-109/l (deep degree of thrombocytopenia), prolongation of index of activated partial thromboplastin time relative to norm before treatment start. Apart from this, the following factors also are among such kind of criteria: decrease of hemoglobin after ATRA prescription before differentiation syndrome development, on-going hypofibrinogenemia and deep degree of thrombocytopenia under concurrent increase of content of urea and creatinine as compared with initial values in treatment dynamics.
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Skol'skaia
authors.forename: L N
authors.initials: LN
authors.lastname: Tarasova
authors.forename: S G
authors.initials: SG
authors.lastname: Vladimirova
authors.forename: V V
authors.initials: VV
authors.lastname: Cherepanova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D002454:Cell Differentiation; D005260:Female; D006402:Hematologic Diseases / Q000097:blood / Q000139:chemically induced / Q000150:complications / Q000503:physiopathology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014212:Tretinoin